Elevance Health Inc. reported stronger revenue and earnings in the first quarter as growing premiums continued to outpace costs, which the company said were meeting its expectations.
The health insurer and health-services provider noted policies it has in place that limit coverage of the high-profile category of diabetes and weight-loss drugs that includes Ozempic. The use and costs of such drugs are rising.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Already a subscriber? Sign In